AMPH

Amphastar Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

22.370

-0.14(-0.622%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.500

Open

22.460

VWAP

22.32

Vol

329.13K

Mkt Cap

1.05B

Low

22.130

Amount

7.35M

EV/EBITDA(TTM)

5.62

Total Shares

48.90M

1.42B

EV/OCF(TTM)

7.36

P/S(TTM)

1.57

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

193.05M

+3.5%

0.841

-8.56%

185.57M

-2.95%

0.819

-14.65%

173.24M

-5.02%

0.742

-21.11%

Estimates Revision

The market is revising Downward the revenue expectations for Amphastar Pharmaceuticals, Inc. (AMPH) for FY2025, with the revenue forecasts being adjusted by -1.68% over the past three months. During the same period, the stock price has changed by -8.36%.

Revenue Estimates for FY2025

Revise Downward

-1.68%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.99%

In Past 3 Month

Stock Price

Go Down

-8.36%

In Past 3 Month

4 Analyst Rating

40.05% Upside

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 31.33 USD with a low forecast of 29.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

40.05% Upside

Current: 22.370

Low

29.00

Averages

31.33

High

35.00

40.05% Upside

Current: 22.370

Low

29.00

Averages

31.33

High

35.00

JPMorgan

Overweight -> Neutral

downgrade

$45 -> $30

2025-05-12

Reason

JPMorgan

Price Target

$45 -> $30

2025-05-12

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Amphastar to Neutral from Overweight with a price target of $30, down from $45. The company has seen continued setbacks on the pipeline front, the analyst tells investors in a research note. The firm says that while Amphastar's generic business remains better positioned than some peers, both glucagon and epinephrine are eroding faster than the Street was expecting. As such, it sees better opportunities elsewhere in the space.

Wells Fargo

Cerena Chen

Overweight

downgrade

$40 -> $35

2025-05-08

Reason

Wells Fargo

Cerena Chen

Price Target

$40 -> $35

2025-05-08

downgrade

Overweight

Reason

Wells Fargo analyst Cerena Chen lowered the firm's price target on Amphastar to $35 from $40 and keeps an Overweight rating on the shares. The firm says that continued expectations for 2 launches this year despite recent CRLs is reassuring though it notes sales contribution would be more meaningful in 2026. Good Baqsimi and Primatene growth make Wells less concerned about competitive pressure elsewhere.

Needham

Serge Belanger

Hold

Reiterates

n/a

2025-04-10

Reason

Needham

Serge Belanger

Price Target

n/a

2025-04-10

Reiterates

Hold

Reason

Piper Sandler

David Amsellem

Hold

Maintains

$36 → $32

2025-03-21

Reason

Piper Sandler

David Amsellem

Price Target

$36 → $32

2025-03-21

Maintains

Hold

Reason

Piper Sandler

David Amsellem

Buy

Hold

Downgrades

$66 → $36

2025-02-04

Reason

Piper Sandler

David Amsellem

Price Target

$66 → $36

2025-02-04

Downgrades

Buy

Hold

Reason

Wells Fargo

Joe Quatrochi

Buy

Initiates

$55

2024-11-22

Reason

Wells Fargo

Joe Quatrochi

Price Target

$55

2024-11-22

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH.O) is 7.11, compared to its 5-year average forward P/E of 15.68. For a more detailed relative valuation and DCF analysis to assess Amphastar Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

15.68

Current PE

7.11

Overvalued PE

20.71

Undervalued PE

10.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

8.95

Current EV/EBITDA

5.91

Overvalued EV/EBITDA

10.73

Undervalued EV/EBITDA

7.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.62

Current PS

1.46

Overvalued PS

3.20

Undervalued PS

2.03

Financials

Annual

Quarterly

FY2025Q1

YoY :

-0.76%

170.53M

Total Revenue

FY2025Q1

YoY :

-22.32%

37.29M

Operating Profit

FY2025Q1

YoY :

-42.21%

25.29M

Net Income after Tax

FY2025Q1

YoY :

-37.04%

0.51

EPS - Diluted

FY2025Q1

YoY :

-47.57%

24.38M

Free Cash Flow

FY2025Q1

YoY :

-4.65%

49.99

Gross Profit Margin - %

FY2025Q1

YoY :

-13.61%

20.56

FCF Margin - %

FY2025Q1

YoY :

-40.99%

14.83

Net Margin - %

FY2025Q1

YoY :

-34.81%

12.55

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

36.6K

USD

3-6

Months

158.7K

USD

6-9

Months

2.4M

USD

0-12

Months

1.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

36.6K

USD

3-6

Months

158.7K

USD

6-9

Months

2.4M

USD

0-12

Months

1.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMPH News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

08:08:48

Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c

2025-07-14 (ET)

2025-07-14

16:14:29

Amphastar announces multi-year expansion of California manufacturing operations

2025-05-21 (ET)

2025-05-21

12:40:57

FTC renews Orange Book listing disputes

News

4.0

05-12Benzinga

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

4.0

05-12Benzinga

JP Morgan Downgrades Amphastar Pharma to Neutral, Lowers Price Target to $30

9.5

05-08NASDAQ.COM

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

People Also Watch

eXp World Holdings Inc

United Natural Foods Inc

Bank of NT Butterfield & Son Ltd

Brookfield Business Corp

FAQ

What is Amphastar Pharmaceuticals Inc (AMPH) stock price today?

The current price of AMPH is 22.37 USD — it has decreased -0.62 % in the last trading day.

AMPH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AMPH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Amphastar Pharmaceuticals Inc (AMPH) stock price today?

What is Amphastar Pharmaceuticals Inc (AMPH)'s business?

What is the price predicton of AMPH Stock?

What is Amphastar Pharmaceuticals Inc (AMPH)'s revenue for the last quarter?

What is Amphastar Pharmaceuticals Inc (AMPH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Amphastar Pharmaceuticals Inc (AMPH)'s fundamentals?

How many employees does Amphastar Pharmaceuticals Inc (AMPH). have?

What is Amphastar Pharmaceuticals Inc (AMPH) market cap?